Compositions including triciribine and methods of use thereof
This invention encompasses combination therapies including TCN, TCN-P, TCN-PM and/or related compounds and one or more additional anti-cancer agents, for example, taxanes a molecule that modulates the HER2/neu (erbB2) receptor, anthracyclin compounds, epidermal growth factor receptor inhibitor compounds, one or more platinum compounds and bortezomib and derivatives thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
1. A diagnostic method for treating a subject having a tumor or cancer, which tumor or cancer overexpresses AKT kinase comprising:
(i) obtaining a biological sample from the subject;
(ii) determining whether the sample overexpresses AKT kinase;
(iii) if said sample overexpresses AKT kinase,
a. administering to said subject:
i. at least one compound of formula I selected from the group consisting of the following compounds:
wherein each R 2 ′, R 3 ′, and R 5 ′ is independently hydrogen; optionally substituted phosphate or phosphonate; mono-, di-, or triphosphate; acyl; lower acyl; alkyl; lower alkyl; amide; sulfonate ester; alkyl sulfonate ester; arylalkyl sulfonate ester; sulfonyl; methanesulfonyl; benzyl sulfonyl, wherein the phenyl group of said benzyl is optionally substituted with one or more halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphoric acid, phosphate, or phosphonate; optionally substituted arylsulfonyl; a lipid; phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group that, in vivo, provides a compound of said formula I wherein R 2 ′, R 3 ′ or R 5 ′ is independently H or mono-, di- or tri-phosphate;
wherein R x and R y are indepenthmtly hydrogen; optionally substituted phosphate; acyl; lower acyl; amide; alkyl; lower alkyl; aromatic; polyoxyalkylenc; polyethyleneglycol; optionally substituted arylsulfonyl; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group; and
wherein R 1 and R 2 each are independently H, optionally substituted straight chained, branched or cyclic alkyl, lower alkyl, alkenyl, or alkynyl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, or aralkylsulfonyl;
ii. trastuzumah or a salt thereof; and
iii. a pharmaceutically acceptable carrier.
2. The composition of claim 1 , wherein the compound of formula I is triciribine.
3. The composition of claim 1 , wherein the compound of formula I is triciribine phosphate.
4. The composition of claim 1 , wherein the compound of formula I is triciribine phosphonate.
5. The composition of claim 1 , wherein the compound of formula I is present in a dose amount of at least 20 mg/m 2 .
6. The composition of claim 1 , wherein the compound of formula I is present in an amount of at least 10 mg/m 2 .
7. The composition of claim 1 , suitable for parenteral administration.
8. The composition of claim 1 , wherein the parenteral administration is intravenous administration.
9. The composition of claim 1 , suitable for oral administration.
10. The composition of claim 1 , suitable for topical administration.
11. The composition of claim 1 , wherein the trastuzumab or a salt thereof is present in an amount from about 1 mg to about 1000 mg.
12. The composition of claim 1 , wherein the trastuzumab or a salt thereof is present in an amount from about 100 mg to about 500 mg.
13. The composition of claim 1 , wherein the trastuzumab or a salt thereof is present in an amount from about 200 mg to about 450 mg.
14. The composition of claim 1 , wherein the trastuzumab or a salt thereof is present in an amount of about 440 mg.
15. The composition of claim 1 , wherein the administration of a compound of formula I and trastuzumab is a single composition.
16. The composition of claim 1 , wherein the administration of a compound of formula I and trastuzumab is concurrently administered.
17. The composition of claim 1 , wherein the administration of a compound of formula I is followed by the administration of trastuzumab.
18. The composition of claim 1 , wherein the administration of trastuzumab is followed by the administration of a compound of formula I.